Avantor (AVTR) fundamentals: P/E, valuation, undervalued?
Avantor · Health Care · ref. ETF XLV · price $15.55
In short — Avantor trades at —× earnings (P/E), 17.7× forward, with a net margin of -8.8 % and revenue growth of +1 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Avantor stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$15.55+11.8% over range
Oct 14, 25low $7.41 · high $15.86Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
11% recommend buying · 9 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
17.7
Forward P/E
—
PEG
1.9
Price/book (P/B)
$10.5B
Market cap
-0.84
EPS
Profitability & growth
-8.8 %
Net margin
+1 %
Revenue growth
-37 %
Earnings growth
$3.7B
Total debt
Avantor income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $7.5B | $662M | 8.8 % |
| 2023 | $7.0B | $321M | 4.6 % |
| 2024 | $6.8B | $712M | 10.5 % |
| 2025 | $6.6B | $-530M | -8.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Avantor's P/E and is the stock undervalued? What's a good P/E?
Avantor's P/E is — (forward 17.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Avantor profitable?
Avantor has a net margin of -8.8 % (EPS -0.84). The company is not (yet) profitable.
Is AVTR stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Avantor? The JPI assistant answers using our backtest data.